CSB 2.009 Note
CSB 2.54 Addition of oral solutions containing dronabinol to schedule II. Section
961.16 (10), Stats., is created to read:
CSB 2.009 Note
961.16 (10) (a) Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution in a drug product approved by the U.S. food and drug administration.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register May 2017 No. 737, eff. 5-15-17;
CR 18-055: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.009 Note
CSB 2.55 Addition of 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA to schedule I. Section
961.14 (4) (tb) 38.,
39.,
40.,
41., and
42., Stats., is created to read:
CSB 2.009 Note
961.14 (4) (tb) 38. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-ADB.
CSB 2.009 Note
39. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as 5F-AMB.
CSB 2.009 Note
40. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as ADB-FUBINACA.
CSB 2.009 Note
41. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate commonly known as MDMB-CHMICA.
CSB 2.009 Note
42. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-FUBINACA.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register May 2017 No. 737, eff. 5-15-17;
CR 17-088: cr.
Register October 2018 No. 754, eff. 11-1-18.
CSB 2.009 Note
CSB 2.56 Addition of 4-fluoroisobutyryl fentanyl to schedule I. Section
961.14 (2) (nd) 10t., Stats., is created to read:
CSB 2.009 Note
961.14 (2) (nd) 10t. 4-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register June 2017 No. 738, eff. 6-12-17;
CR 17-089: cr.
Register October 2018 No. 754, eff. 11-1-18.
CSB 2.009 Note
CSB 2.57 Scheduling of cyclopropyl fentanyl. Section
961.14 (2) (nd) 10d., Stats., is created to read:
CSB 2.009 Note
961.14 (2) (nd) 10d. Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
CSB 2.009 History
History:
EmR 1716: emerg. cr. eff. 9-8-17; CR
17-0785: cr.
Register July 2018 No. 751, eff. 8-1-18; corrections made under s.
35.17, Stats.,
Register July 2018 No. 751.
CSB 2.009 Note
961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2017 No. 743, eff. 11-20-17;
CR 18-024: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.009 Note
CSB 2.59 Addition of ortho-fluorofentanyl to schedule I. Section
961.14 (2) (nd) 16m., Stats., is created to read:
CSB 2.009 Note
961.14 (2) (nd) 16m. Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register December 2017 No. 744, eff. 12-4-17; correction made under s.
35.17, Stats.,
Register December 2017 No. 744;
CR 18-023: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.009 Note
CSB 2.60 Addition of FUB-AMB to schedule I. Section
961.14 (4) (tb) 43., Stats., is created to read:
CSB 2.009 Note
961.14 (4) (tb) 43. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as FUB-AMB, MMB-FUBINACA or AMB-FUBINACA.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register December 2017 No. 744, eff. 12-11-17; correction made under s.
35.17, Stats.,
Register December 2017 No. 744;
CR 18-022: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.009 Note
CSB 2.61 Addition of MT-45 to schedule I. Section
961.14 (2) (rk), Stats., is created to read:
CSB 2.009 Note
961.14 (2) (rk) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register January 2018 No. 745, eff. 1-22-18; correction made under s.
35.17, Stats.,
Register January 2018 No. 745;
CR 18-069: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.009 Note
CSB 2.62 Addition of para-chloroisobutyryl fentanyl to schedule I. Section
961.14 (2) (nd) 16s., Stats., is created to read:
CSB 2.009 Note
961.14 (2) (nd) 16s. Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2018 No. 747, eff. 3-12-18;
CR 18-070: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.009 Note
CSB 2.63 Addition of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA to schedule I. Section
961.14 (4) (tb) 44.,
45.,
46.,
47., and
48., Stats., are created to read:
CSB 2.009 Note
961.14 (4) (tb) 44. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, commonly known as NM2201.
CSB 2.009 Note
45. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, commonly known as 5F-AB-PINACA.
CSB 2.009 Note
46. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 4-CN-CUMYL-BUTINACA.
CSB 2.009 Note
47. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-CHMICA.
CSB 2.009 Note
48. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2018 No. 747, eff. 3-12-18; cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2018 No. 752, eff. 8-13-18; correction made under s.
35.17, Stats.,
Register August 2018 No. 752;
CR 19-010: cr.
Register June 2020 No. 774, eff. 7-1-20; correction made under s.
35.17, Stats.,
Register June 2021 No. 786.
CSB 2.009 Note
CSB 2.64 Addition of N-Ethylpentylone to schedule I. Section
961.14 (7) (L) 34., Stats., is created to read:
CSB 2.009 Note
961.14 (7) (L) 34. N-Ethylpentylone, commonly known as ephylone.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2018 No. 754, eff. 10-8-18;
CR 19-011: cr.
Register June 2020 No. 774, eff. 7-1-20.
CSB 2.009 Note
CSB 2.65 Addition of approved cannabidiol drugs to schedule V. Section
961.22 (7), Stats., is created to read:
CSB 2.009 Note
961.22 (7) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4g), Stats.,
Register October 2018 No. 754, eff. 10-15-18;
CR 19-012: cr.
Register June 2020 No. 774, eff. 7-1-20.
CSB 2.009 Note
CSB 2.66 Addition of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 to schedule I. Section
961.14 (4) (tb),
49.,
50.,
51.,
52., and
53., Stats., are created to read:
CSB 2.009 Note
961.14 (4) (tb) 49. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA.
CSB 2.009 Note
50. Methyl 2-(1-(5-fluoropentyl)-1-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PICA.
CSB 2.009 Note
51. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as FUB-AKB48, FUB-APINACA or AKB48 N-(4-FLUOROBENZYL).
CSB 2.009 Note
52. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 5F-CUMYL-PINACA or SGT-25.
CSB 2.009 Note
53. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, commonly known as FUB-144.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2019 No. 759, eff. 3-11-19;
CR 20-048: cr.
Register June 2021 No. 786, eff. 7-1-21.
CSB 2.009 Note
CSB 2.67 Addition of Brexanolone and Solriamfetol to schedule IV. Section
961.20 (2) (ap) and
(2m) (g), Stats., are created to read:
CSB 2.009 Note
961.20 (2) (ap) Brexanolone;
CSB 2.009 Note
(2m) (g) Solriamfetol.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2019 No. 763, eff. 7-22-19;
CR 20-049: cr.
Register June 2021 No. 786, eff. 7-1-21; correction in (2) (ap) made under s.
35.17, Stats.,
Register June 2021 No. 785.
CSB 2.009 Note
CSB 2.68 Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP to schedule I. Section
961.14 (7) (L) 35. to
40., Stats., is created to read:
CSB 2.009 Note
961.14 (7) (L) 35. N-Ethylhexedrone.
CSB 2.009 Note
36. Alpha-pyrrolidinohexanophenone, commonly known as a-PHP.
CSB 2.009 Note
37. 4-methyl-alpha-ethylainopentiophenone, commonly known as 4-MEAP.
CSB 2.009 Note
38. 4'-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.
CSB 2.009 Note
39. Alpha-pyrrolidinoheptaphenone, commonly known as PV8.
CSB 2.009 Note
40. 4'-chloro-alpha-pyrrolidinovalerophenone, commonly known as 4-chloro-a-PVP.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4g), Stats.,
Register August 2019 No. 764, eff. 8-19-19;
CR 20-050: cr.
Register June 2021 No. 786, eff. 7-1-21.
CSB 2.009 Note
CSB 2.69 Addition of Noroxymorphone to schedule II. Section
961.16 (2) (a) 10m., Stats., is created to read:
CSB 2.009 Note
961.16 (2) (a) 10m. Noroxymorphone.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2019 No. 767, eff. 11-11-19;
CR 20-051: cr.
Register June 2021 No. 786, eff. 7-1-21.
CSB 2.009 Note
CSB 2.70 Scheduling 4F-MDMB-BINACA and MMB-FUBICA. Section
961.14 (4) (tb) 38m. and
43m., Stats., are created to read:
CSB 2.009 Note
961.14 (4) (tb) 38m. Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA.
CSB 2.009 Note
43m. Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-FUBICA or AMB-FUBICA.
CSB 2.009 History
History:
EmR2017: emerg. cr., eff. 6-26-20;
CR 20-022: cr.
Register May 2021 No. 785, eff. 6-1-21.
CSB 2.009 Note
CSB 2.71 Addition of lasmiditan to schedule V. Section
961.22 (8), Stats., is created to read:
CSB 2.009 Note
961.22 (8). Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide].
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2020 No.771, eff. 3-23-20;
CR 20-058: cr.
Register July 2021 No. 787, eff. 8-1-21.
CSB 2.009 Note
CSB 2.72 Scheduling of isotonitazene and 1P-LSD. Section
961.14 (2) (pe) and
(4) (jm), Stats., are created to read:
CSB 2.009 Note
961.14 (2) (pe) Isotonitazene;
CSB 2.009 Note
961.14 (4) (jm) 1-propionyl-lysergic acid diethylamide, commonly known as 1P-LSD;
CSB 2.009 History
History:
EmR2013: emerg. cr., eff. 6-5-20;
CR 20-023: cr.
Register May 2021 No. 785, eff. 6-1-21; correction made under s.
35.17, Stats.,
Register May 2021 No. 785.
CSB 2.009 Note
CSB 2.73 Addition of cenobamate to schedule V. Section
961.22 (9), Stats., is created to read:
CSB 2.009 Note
961.22 (9) CENOBAMATE Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester)
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register May 2020 No. 773, eff. 5-18-20;
CR 20-075: cr.
Register July 2021 No. 787, eff. 8-1-21.
CSB 2.009 Note
CSB 2.74 Addition of Lemborexant to schedule IV. Section
961.20 (2) (eqm), Stats., is created to read:
CSB 2.009 Note
961.20 (2) (eqm) Lemborexant.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2020 No.771, eff. 5-18-20;
CR 20-076: cr.
Register July 2021 No. 787, eff. 8-1-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787.
CSB 2.009 Note
CSB 2.75 Exclusion of approved cannabidiol drugs from schedule I. (1) Section
961.14 (4) (t) 4., Stats., is created to read:
CSB 2.009 Note
961.14 (4) (t) 4. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.009 Note
(2) Section 961.22 (7) is repealed.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4g), Stats.,
Register June 2020 No. 774, eff. 6-29-20;
CR 20-077: cr.
Register July 2021 No. 787, eff. 8-1-21.
CSB 2.009 Note
CSB 2.76 Addition of norfentanyl to schedule II. (1) Section 961.16 (8) (b), Stats., is renumbered 961.16 (8) (b) (intro.) and amended to read:
CSB 2.009 Note
961.16 (8) (b) An immediate precursor to fentanyl, including all of the following:
